ALK and non-small cell lung carcinoma: Crizotinib, an analog of TQ-B3101M has been approved worldwide for the treatment of non-small-cell lung cancers (NSCLC) with rearrangements involving ALK or ROS1-positive in adults (Wang et al., 2016; Balis et al., 2017).